

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-11 (Canceled).

Claim 12 (Withdrawn). A method for inhibiting Helicobacter pylori colonization in mammals including humans, comprising orally administering to a mammal a glycoprotein which specifically binds to urease of Helicobacter pylori in an effective amount for inhibiting Helicobacter pylori colonization, the glycoprotein being obtained by isolation and purification from a glycoprotein-containing substance using a method which utilizes specific adsorption to Helicobacter pylori.

Claim 13 (Withdrawn). A method for inhibiting Helicobacter pylori colonization in mammals including humans, comprising orally administering to a mammal a glycoprotein which specifically binds to urease of Helicobacter pylori and an inhibitor of gastric acid secretion in an effective amount for inhibiting Helicobacter pylori colonization, the glycoprotein being obtained by isolation and purification from a glycoprotein-containing substance using a method which utilizes specific adsorption to H. pylori urease.

Claim 14 (Withdrawn). A method for preventing or treating a disease caused by or associated with Helicobacter pylori in mammals including humans, comprising orally administering to a mammal a glycoprotein which specifically binds to urease of Helicobacter pylori in an effective amount for preventing or treating the disease, the glycoprotein being obtained by isolation and purification from a glycoprotein-containing substance using a method which utilizes specific adsorption to Helicobacter pylori urease.

Claim 15 (Withdrawn). A method for preventing or treating a disease caused by or associated with Helicobacter pylori in mammals including humans, comprising orally administering to a mammal a glycoprotein which specifically binds to urease of Helicobacter pylori in an inhibitor of gastric acid secretion in an effective amount for preventing or treating the disease, the glycoprotein being obtained by isolation and purification from a glycoprotein-containing substance using a method which utilizes specific adsorption to Helicobacter pylori urease

Claims 16-21 (Canceled).

Claim 22 (Currently Amended). An inhibitor of *Helicobacter pylori* colonization, consisting essentially of a glycoprotein which is prepared by contacting a glycoprotein-containing substance from whey of bovine milk or albumen of chicken eggs with

Helicobacter pylori urease and isolating and purifying the glycoprotein specifically bound to the urease consisting of the glycoprotein according to Claim 16.

Claim 23 (Currently Amended). A pharmaceutical composition for preventing or treating a gastrointestinal disease caused by or associated with *Helicobacter pylori* in mammals ~~including humans~~, comprising the inhibitor glycoprotein according to Claim 22 ~~16~~.

Claim 24 (Currently Amended). A food which prevents or treats a gastrointestinal disease caused by or associated with *Helicobacter pylori* in mammals ~~including humans~~ when consumed in an effective amount, comprising the inhibitor glycoprotein according to Claim 22 ~~16~~.

Claim 25 (Currently Amended). An inhibitor composition of *Helicobacter pylori* colonization, comprising the inhibitor glycoprotein according to Claim 22 ~~16~~ and an inhibitor of gastric acid secretion.

Claim 26 (Currently Amended). A pharmaceutical composition for preventing or treating a gastrointestinal disease caused by or associated with *Helicobacter pylori* in mammals ~~including humans~~, comprising the inhibitor glycoprotein according to Claim 22 ~~16~~ and an inhibitor of gastric acid secretion.

Claim 27 (Previously Presented). A process for preparing a glycoprotein which specifically binds to urease of *Helicobacter pylori*, comprising contacting a glycoprotein-containing substance with *Helicobacter pylori* urease and isolating and purifying the glycoprotein specifically bound to the urease.

Claim 28 (Previously Presented). The process according to Claim 27, wherein said contacting step involves affinity chromatography using a column on which the urease is immobilized.

Claim 29 (Previously Presented). A process for preparing an inhibitor of *Helicobacter pylori* colonization, comprising contacting a glycoprotein-containing substance with *Helicobacter pylori* urease and isolating and purifying the glycoprotein specifically bound to the urease.

Claim 30 (Previously Presented). The process according to Claim 29, wherein said contacting step involves affinity chromatography using a column on which the urease is immobilized.

Claim 31 (New) The inhibitor according to Claim 22, wherein said contacting step involves affinity chromatography using a column on which the urease is immobilized.

Claim 32 (New). The inhibitor according to Claim 22, wherein the urease immobilized on the column is recombinant urease.

Claim 33 (New). The inhibitor according to Claim 22, wherein the glycoprotein-containing substance is high molecular weight whey concentrate.

Claim 34 (New). The inhibitor according to Claim 22, wherein the glycoprotein-containing substance is high molecular weight albumen protein concentrate.
